Divi's Laboratories AAQS
The The AAQS of Divi's Laboratories (DIVISLAB.NS) as of Aug 14, 2026 is 7. In the previous year, The AAQS was 7.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
7
YoY
0.00%
Last updated:
Divi's Laboratories has a current AAQS of 7.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Divi's Laboratories in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Divi's Laboratories in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Access this data via the Eulerpool API
Divi's Laboratories Stock analysis
What does Divi's Laboratories do? Divi's Laboratories Ltd. is a pharmaceutical company based in Hyderabad, India. It was founded in 1990 and has become one of the leading manufacturers of active ingredients and formulations for the pharmaceutical industry in recent years. The company was founded by Dr. Murali Divi, who built the company on principles of quality, technology, and innovation. Divi's Laboratories now employs approximately 13,000 employees and operates production facilities in India and the USA. The company operates in various sectors, including generics, custom synthesis, research and development, and nutraceuticals. Its products are used worldwide and are approved in over 95 countries. Divi's Laboratories follows a vertically integrated supply chain model, producing high-quality active ingredients and developing its own formulations for the pharmaceutical industry. The company always relies on innovative technologies and continuous improvement of product quality. Its product range includes a wide range of active ingredients for various therapeutic areas, such as antibiotics, antidepressants, antihypertensives, antidiabetics, static lipid-lowering agents, and antipsychotics. Divi's Laboratories has state-of-the-art production facilities, strict quality controls, and advanced analytical facilities for all pharmaceutical ingredients. In addition to its active ingredients, the company is also known for its custom synthesis services, which involve the production of customer-specific active ingredients for the pharmaceutical industry. Divi's Laboratories offers a tailored service that meets the specific requirements of customers, ranging from the development of new active ingredients and formulations to the production of small or medium quantities of active ingredients. In the area of research and development, Divi's Laboratories works closely with academic institutions and other pharmaceutical companies to leverage the latest scientific knowledge and develop innovative products. The company invests a significant sum in research and development annually. In addition to active ingredients and custom synthesis services, Divi's Laboratories also offers a range of nutraceuticals. These products, such as vitamins, minerals, and other dietary supplements, are used to support a healthy lifestyle. In summary, Divi's Laboratories is an India-based pharmaceutical company specializing in the manufacture of active ingredients and formulations for the pharmaceutical industry. The company operates to the highest quality standards and relies on innovative technologies and sustainable product development. The wide product range and custom synthesis services offer customers a tailored solution for their needs. Divi's Laboratories is a leading provider of active ingredients and has made a name for itself in the pharmaceutical and nutraceutical industry due to its high quality and productivity. Divi's Laboratories is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Divi's Laboratories stock
The AAQS of Divi's Laboratories is 7 in 2026.
On Eulerpool you can find the complete historical development of The AAQS Divi's Laboratories since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
Quality — Divi's Laboratories
All Key Metrics — Divi's Laboratories
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth